News
The RESOLUTE phase III trial of AstraZeneca’s Fasenra (benralizumab), despite showing numerical improvement, did not achieve statistical significance in the primary endpoint in patients with chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback